David L. Wyles, MD
Associate Professor of Medicine
University of California San Diego
La Jolla, CA

Research Topics

• Hepatitis C virus (HCV) and HIV coinfection
• In vitro assessment of novel antiviral drugs
• HCV resistance
• Viral fitness
• Early clinical trials of new antiviral drugs (phase I and II)
  
  

Lecture and Writing Topics

• HCV-HIV coinfection, clinical care and treatment, new antiviral drugss and viral resistance
• Hepatitis B virus (HBV) and HIV coinfection, treatment, and nucleoside/nucleotide analogue reverse transcriptase inhibitor resistance
  
  

Current Professional Summary

Dr Wyles is an Assistant Professor of Medicine at the University of California San Diego. His research interests include the in vitro evaluation of new anti-HCV compounds and early phase I/II clinical trials of anti-HCV compounds. He serves as an attending physician on the infectious diseases and internal medicine services at the University of California San Diego teaching hospitals. He is an Instructor in the School of Medicine Medical Microbiology laboratory course.

Committees and Organizations

• Member, Infectious Diseases Society of America
• Member, American Society for Microbiology
• Contributor, Expert Perspectives III: Strategies for the Management of HIV/HCV Co-Infection (2002)
• Advisor/Instructor, Colorado AIDS Education and Training Center: Hepatitis C Virus Center for Excellence (2002-2005)
• Consultant, Colorado AIDS Education and Training Center: Hepatitis C Virus Center for Excellence (2005-present)
  
  

Honors and Awards

• Tau Beta Pi, Engineering Honor Society
• GlaxoSmithKline HIV Fellow
  
  

Education

• Northwestern University, BS Biomedical Engineering (1993)
• Northwestern University Feinberg School of Medicine, MD (1998)
• University of Colorado Health Sciences Center, Residency in Internal Medicine (1998-2001)
• University of Colorado Health Sciences Center, Fellowship in Infectious Diseases (2001-2004)
  
  
  

Selected Publications

1. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40:174-181.
2. Wyles DL, Gerber JG. Abacavir pharmacokinetics in hepatic dysfunction. Clin Infect Dis. 2005;40:909-910.
3. Wyles DL, Kaihara KA, Vaida F, Schooley RT. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol. 2007;81:3005-3008.
4. Grünberger C, Wyles DL, Kaihara KA, Schooley RT. Three-drug synergistic interactions of small molecular inhibitors of HCV replication. J Infect Dis. 2008;197:42-45.
5. Wyles DL, Patel A, Madinger N, Bessesen M, Krause PR, Weinberg A. Development of herpes simplex virus disease in patients who are receiving cidofovir. Clin Infect Dis. 2005;41:676-680.